Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$21.21
-0.2%
$24.34
$13.40
$26.65
$3.59B0.752.16 million shs2.78 million shs
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$15.32
-2.2%
$17.04
$13.50
$25.67
$3.74B0.543.32 million shs2.05 million shs
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$5.17
-5.8%
$4.32
$1.03
$5.97
$1.18B1.555.10 million shs5.63 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$64.70
-1.9%
$57.29
$33.31
$66.70
$4.10B2.221.05 million shs806,300 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-9.92%-12.15%-16.03%-4.28%+34.22%
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
-2.00%+0.64%-7.94%-14.89%-18.82%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-2.14%+19.09%+15.82%+144.00%+365.25%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+1.37%+11.36%+15.95%+19.43%+41.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$21.21
-0.2%
$24.34
$13.40
$26.65
$3.59B0.752.16 million shs2.78 million shs
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$15.32
-2.2%
$17.04
$13.50
$25.67
$3.74B0.543.32 million shs2.05 million shs
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$5.17
-5.8%
$4.32
$1.03
$5.97
$1.18B1.555.10 million shs5.63 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$64.70
-1.9%
$57.29
$33.31
$66.70
$4.10B2.221.05 million shs806,300 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-9.92%-12.15%-16.03%-4.28%+34.22%
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
-2.00%+0.64%-7.94%-14.89%-18.82%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-2.14%+19.09%+15.82%+144.00%+365.25%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+1.37%+11.36%+15.95%+19.43%+41.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.65
Moderate Buy$29.5339.22% Upside
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6780.59% Upside
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.17
Buy$11.25117.60% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.00
Buy$68.365.66% Upside

Current Analyst Ratings Breakdown

Latest ATAI, ACAD, PTGX, and ADMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$30.00 ➝ $28.00
9/23/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$15.00
9/17/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$80.00
9/17/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$72.00
9/16/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$72.00
9/12/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/12/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$73.00
9/11/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/11/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$35.00 ➝ $39.00
9/9/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$36.00 ➝ $39.00
8/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
(Data available from 9/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$957.80M3.74$0.70 per share30.16$4.40 per share4.82
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M8.57$0.53 per share28.93$1.48 per share10.35
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$310K3,574.64N/AN/A$0.69 per share7.49
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$434.43M9.26$4.43 per share14.60$11.33 per share5.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$226.45M$1.3315.9527.915.3921.80%14.69%9.41%11/5/2025 (Estimated)
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8617.8122.20N/A44.06%41.01%28.47%11/6/2025 (Estimated)
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$149.27M-$0.69N/AN/AN/AN/A-85.43%-64.38%11/12/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$275.19M$0.7092.43N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)

Latest ATAI, ACAD, PTGX, and ADMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.12-$0.14-$0.02-$0.14N/A$0.72 million
8/6/2025Q2 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.14$0.16+$0.02$0.16$263.07 million$264.57 million
8/6/2025Q2 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.14$0.15+$0.01$0.14$121.77 million$121.98 million
8/6/2025Q2 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.91
2.83
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.21
5.33
2.78
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
0.02
4.02
4.02
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
16.97
16.97

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
28.41%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.50%
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.50%
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
26.80%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510168.71 million124.00 millionOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.63 million230.28 millionOptionable
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
80214.34 million156.90 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12062.21 million59.16 millionOptionable

Recent News About These Companies

Barclays Initiates Coverage on Protagonist Therapeutics (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory 

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.21 -0.05 (-0.24%)
Closing price 04:00 PM Eastern
Extended Trading
$21.10 -0.12 (-0.54%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$15.32 -0.34 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$15.42 +0.09 (+0.62%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

atai Life Sciences stock logo

atai Life Sciences NASDAQ:ATAI

$5.17 -0.32 (-5.83%)
Closing price 04:00 PM Eastern
Extended Trading
$5.11 -0.06 (-1.16%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$64.70 -1.25 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$64.10 -0.60 (-0.93%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.